Pharmacoeconomic Analysis of Various Rheumatoid Arthritis Treatment Regimens

The article presents a pharmacoeconomic study of the use of generic metho- trexate (Methortrit and Metoject) in the treatment of rheumatoid arthritis (RA). This re- search is timely because RA is the second most common morbidity in Russia, and the number of patients with RA and the cost of their treatment are increasing every year. We have compared the efficacy and cost of two regimens used in RA treatment, and re- vealed that a therapy with Methortrit is more expensive than a regimen with Metoject. The lower cost of Metoject compared to Methortrit with comparable efficacy and safety contributes to the overall cost-effectiveness of the treatment. The findings of the study may be useful for making rational decisions on pharmacotherapy for RA, taking into account economic aspects.